PetCaseFinder

Peer-reviewed veterinary case report

Treatment of stubborn nasal fungal infection in 10 dogs

By Stewart, J & Bianco, D·Published in The Journal of small animal practice·2017·Advanced Critical Care Emergency and Specialty Services, United States·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Treatment of refractory sino-nasal aspergillosis with posaconazole and terbinafine in 10 dogs.

Species:
dog

Plain-English summary

Ten dogs with a serious nasal infection called sino-nasal aspergillosis, which didn't improve with standard treatments, were given a combination of two antifungal medications: posaconazole and terbinafine. They took these medications for several months, and the results were promising—seven dogs showed complete recovery while three had partial improvement. All the dogs lived for more than a year after starting the treatment, although two did experience a relapse after stopping the medications. Overall, the treatment was safe and well-tolerated, with no significant side effects reported.

People also search for: dog nasal infection treatment · sino-nasal aspergillosis in dogs · posaconazole for dogs · terbinafine for dog infections

Abstract

OBJECTIVES: To determine the safety and efficacy of posaconazole and terbinafine for the treatment of naturally occurring sino-nasal aspergillosis in dogs refractory to conventional topical and systemic treatment. MATERIALS AND METHODS: Ten client-owned dogs with sino-nasal aspergillosis and not responsive to conventional treatments were prospectively enrolled to receive a dose of 5 mg/kg posaconazole orally every 12 hours for six months. All dogs were concurrently treated with doses of 30 mg/kg terbinafine orally every 12 hours and 5 mg/kg doxycycline orally every 12 hours for 6 to 18 months. RESULTS: All 10 enrolled dogs completed the study. The treatment response was defined as complete clinical remission (n=7) or partial clinical remission (n=3). Two dogs relapsed after cessation of combination therapy. All dogs lived more than one year after starting combination therapy and eight dogs are alive at the time of writing. No clinically relevant adverse reactions or increases in hepatic enzyme activity occurred during the combination therapy. CLINICAL SIGNIFICANCE: The results of this study suggest that this combination therapy appears safe and well-tolerated for the treatment of refractory sino-nasal aspergillosis in dogs. Long-term survival is possible with prolonged treatment, but relapse is possible. Larger prospective studies are warranted to further evaluate these preliminary findings.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/28485470/